it is an analog of n n n triethylenephosphoramide tepa which contains tetrahedral phosphorus and is structurally akin to phosphate it is manufactured by heating aziridine with thiophosphoryl chloride thiotepa was developed by the american cyanamid company in the early 1950s and reported to media outlets in 1953 in 1959 thiotepa was registered with the food and drug administration fda as a drug therapy for several solid cancers on january 29 2007 the european medicines agency designated thiotepa as an orphan drug on april 2 2007 the united states fda designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation adienne pharma biotech italy the owner of thiotepa tepadina applied for these designations thiotepa is indicated for use in combination with other chemotherapeutic agents this can be with or without total body irradiation tbi as a conditioning treatment prior to allogeneic or autologous hematopoietic progenitor cell transplantation hpct in hematological diseases in adult and pediatric patients these diseases include hodgkin s disease and leukaemia thiotepa is also used with high dose chemotherapy with hpct support to treat certain solid tumors in adult and pediatric patients thiotepa is used in the palliation of many neoplastic diseases the